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Direct gene transfer into skeletal muscle is a potential therapeutic strategy for inherited primary myopathies uch as Duchenne muscular dystrophy 
(DMD). In order to affect the life-expectancy of these patients, it will be necessary to carry out gene therapy on the diaphragm. To this end, we 
report efficient introduction of pure recombinant plasmid DNA into the mouse diaphragm, without causing significant damage. Application of 
this approach to the diaphragm of the mdx mouse will provide information on the potential usefulness of gene therapy for the treatment of DMD 
patients. 
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1. INTRODUCTION 
Many of the primary myopathies are known or 
thought to be caused by single gene defects, and thus 
represent potential candidates for gene therapy. The 
most prevalent primary myopathy is the Duchenne 
form of muscular dystrophy (DMD), a fatal X-linked 
recessive disorder affecting 1 in 3,500 males [l]. DMD 
is characterized by progressive muscular atrophy and 
degeneration with concomitant loss of function [2]. The 
genetic defect responsible for this disease is located at 
Xp21 and prevents the production of dystrophin, a 
large (427 kDa) structural protein associated with the 
sarcolemma [3-51. The muscle pathology consists of 
persistent cycles of degeneration and regeneration with 
eventual failure to regenerate leading to the replacement 
of myofibres by fatty and fibrotic tissue. Essentially all 
skeletal muscles, including the diaphragm are affected, 
and death, which occurs in the second or third decade 
of life, most often results from respiratory insufficiency. 
In attempts to develop therapeutic strategies for 
DMD, direct gene transfer into muscle has been evalu- 
ated in animal models. Reporter genes have been suc- 
cessfully introduced into hindlimb muscles of mice 
using pure plasmid DNA [&lo], adenovirus [6,1 l-131 
or retrovirus [6,14]. Although these results are encour- 
aging, particularly with adenovirus and pure plasmid 
DNA, the efficiency of transfer is still insufficient to 
consider human trials. In addition, a major concern has 
been the potential difficulty to carry out direct gene 
transfer on the diaphragm and/or intercostal muscles, 
which would be essential in order to affect the life expec- 
tancy of these patients. 
*Corresponding author. Fax: (1) (613) 787 6675. 
As part of our on-going studies using direct gene 
transfer to study the physiological regulation of mem- 
brane and cytoskeletal proteins in muscle, we investi- 
gated the feasibility of introducing new genetic material 
into the diaphragm. Here we report the development of 
an approach that successfully allows the uptake and 
expression of pure recombinant plasmid DNA by a 
large number of muscle fibres in the mouse diaphragm, 
without causing significant damage. These findings 
have implications for the treatment of primary myopa- 
thies such as DMD. 
2. MATERIALS AND METHODS 
2.1. Expression vectors 
Recombinant plasmid DNA containing Escherichiu coli IucZ for 
/J-galactosidase @gal) as reporter gene driven by the cytomegalovirus 
(CMV) promoter [15] (pCMV-la@, as previously reported [16], was 
prepared by the Qiagen (Chatsworth, CA) mega-prep rocedure. The 
DNA was recovered by ethanol precipitation, then redissolved in 
water, aliquoted and stored at -80°C until required for injection. 
2.2. In vivo gene transfer into diaphragm 
Gene transfer was carried out on diaphragms of male C57BU6J 
mice (Charles River) aged 67 weeks (2&21 g), under anesthesia 
(sodium pentobarbital, 75 mg/kg i.p.). The inferior surface of the left 
hemi-diaphragm was exposed via a 2 cm incision made inferior to the 
lateral costal margin. While holding the costal margin such that the 
peripheral muscular part of the hemi-diaphragm was flattened, the 
DNA solution (pCMV-lac2, 2 &,~l; in 0.1 M PBS, pH 7.4) was 
injected at several sites between the inferior surface of the muscle and 
the overlying epimysium. With the aid of a surgical microscope, this 
was carried out using a 1 ml TB syringe and a 30 g needle. The needle 
was inserted, orifice side away from the muscle, until the entire beveled 
portion was contained within the fascia. Each hem&diaphragm re- 
ceived a total volume of 50 ,~l in 4-8 individual injections placed 
around the perimeter of the muscle. The contralateral hemi-dia- 
phragm served as an untreated control. Subsequent to DNA injection, 
abdominal musculature and skin were closed with 5.0 silk and wound 
clips, respectively. 
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2.3. Histochemistry 
Five days after gene transfer, the entire diaphragm was removed 
and stained for activity of B-gal either in the whole muscle of on 
cryostat cross-sections. 
For staining of whole muscle, the entire diaphragm, still attached 
to the inferior ribs and xiphoid process, was removed and pinned onto 
paraffin in a Petri dish. Staining was carried out with a modification 
of the method of Sanes et al. [17]. Specimens were fixed for 4-16 h at 
4OC in 2% paraformaldehyde, 2 mM MgCl, and 1.25 mM EDNA in 
PBS (0.1 M, pH 7.4), rinsed 3 x 30 min in PBS at 4°C and pre- 
incubated in detergent solution (2 mM MgCI,, 5 mM potassium ferro- 
cyanide, 5 mM potassium ferricyanide, 0.01% sodium deaoxycholate 
and 0.02% Nonidet NP 40 in PBS). Incubation was for 4-8 h at 37°C 
in detergent solution containing 400 mg/ml 5-bromo-4-chloro-3-m 
dolyl-B-o-galactosidase (X-Gal). The X-Gal was first dissolved in 
DMFO as a 4% w/v stock, which was stored at -20°C. Following 
incubation, muscles were rinsed in PBS and stored in the fixative 
solution at 4°C. 
For cryostat sectioning, individu~ hemi-~aph~~s were dissected 
from the ribs and wrapped around a piece of liver, then were frozen 
in isopentane cooled by liquid N,. The entire muscle was sectioned (12 
pm), and every tenth section was collected onto a gelatinized slide and 
stained for p-gal by a modification of the method of Dannenburg and 
Suga [18]. Sections were fixed for 15 min at 4°C in 1% glutaraldehyde 
in PBS, rinsed 3 x 5 min in PBS at 4°C incubated for 2-6 h at 37°C 
(PBS containing X-Gal at 400 mglml, 1 mM MgCl,, 5 mM potassium 
ferrocyanide and 5 mM potassium ferricyanide; X-Gal made from 
stock as above), rinsed 2 x 5 min in PBS, counterstained in alcoholic 
eosin (1 min in 0.25%), dehydrated through graded alcohols, cleared 
in xylene and mounted in Permount. Serial sections to those stained 
for B-gal were also stained by (i) routine haematoxylin and eosin 
(H&E), to detect he presence of centronuci~tion, or (ii) immunohis- 
tochemical detection of embryonic and neonatal isoforms of myosin 
heavy chain (MyHC) using the BF-45 antibody of Schiaffino et al. (191. 
3. RESULTS AND DISCUSSION 
3. I. Ef$cierzt ransfer of DNA into mas~le~bres of dia- 
p~~agrn 
In contrast to methods we have recently developed 
for efficient transfer of genetic material directly into 
mouse hindlimb muscle, in which pure DNA or viral 
vectors are injected intramuscularly following pre-treat- 
ment with hypertonic sucrose [7] or in regenerating mus- 
cles [6J, we decided upon an alternative approach owing 
to the thinness of diaphragm muscle. Sub-epimysial in- 
jection of plasmid DNA (pCMV-EacZ) into mouse dia- 
phragm resulted in uptake and expression of the lac.2 
reporter gene. As shown in Fig. la, each injection re- 
sulted in staining of several fibres in the vicinity of the 
injection site. Fibres were frequently stained along their 
entire length, from the costal margin to the central ten- 
don. Although the DNA was applied to only the inferior 
surface of the diaphragm, all injections resulted in stain- 
ing of both superficial and deeper fibres, with several 
injection sites exhibiting p-gal expressing fibres accross 
the entire 10-12 cell thickness of the muscle (Figs. lb, 
2a and 2~). Individual injection sites resulted in 41 If: 3 
stained muscle fibres (x + S.E.M., n = 8), which is supe- 
rior to results obtained with injection of similar quanti- 
ties of pCMV-facZ into hindlimb mouse muscle. Sur- 
prisingly, the present results compare favorably with 
those obtained with injection of DNA into sucrose pre- 
treated tibialis anterior (TA) muscle, in which a single 
injection of 4-5 times more DNA resulted in only 36 + 7 
IacZ-expressing fibres (n = 6) [6]_ This may reflect better 
diffusion of the DNA within the diaphragm, which may 
occur as a result of a less dense endomysium and/or an 
assistive action of its rhythmic contractions. 
3.2. Sub-epimysial injection causes minimal damage 
In our previous studies on gene transfer into TA mus- 
cle, intramuscular injection of DNA caused damage to 
a large number of fibres, which underwent a cycle of 
degeneration and regeneration [7]. Sub-epimysial injec- 
tion of DNA, however, resulted in little or no damage 
to muscle fibres in the diaphragm, as evidenced by the 
paucity of fibres having centrally placed nuclei (Fig. 2a 
and b) or containing immature (embryonic and neona- 
tal) isoforms of MyHC (Fig. 2c and d). Furthermore, 
when damaged and/or regenerating fibres were ob- 
served, they were usually restricted to the first two lay- 
ers of muscle cells on the surface of the diaphragm 
i~ediately adjacent to the injection site (Fig. 2e-g). 
An additional concern in these experiments, was the 
effect of the multiple injection procedure per se on the 
normal functioning of the diaphragm. During the injec- 
tions, the rhythm of diaphragmatic contractions was 
undisturbed. Furthermore, animals recovered quickIy 
post-o~ratively and did not appear to present any par- 
ticular signs of discomfort or respiratory distress. Thus, 
this injection procedure does not seem to have deleteri- 
ous consequences for the animal. 
3.3. Therapeutic implications 
The results reported here represent he first demon- 
stration of direct gene transfer into diaphragm muscle. 
Furthermore, they show that sub-epimysial injection of 
diaphragm is safe and results in efficient gene transfer 
while causing minimal myofibre damage. Our results 
thus can be applied to the mdx mouse to provide a 
model with which to investigate the potential usefulness 
of gene therapy for DMD. The mdx mouse [20], which 
like DMD has a virtual lack of dystrophin, has been 
limited as an experimental model since its muscles, with 
the apparent exception of the diaphragm, fail to develop 
si~ificant patholo~~al changes 1211. We are currently 
testing the ability of full-length and mini-dystrophin 
Fig. 1. Sub-epimysial injection of plasmid DNA results in uptake and expression of ZacZ reporter gene in diaphragm muscle fibers. Diaphragm 
stained for activity of @-pal in the whole muscle (A) or cryostat section (B) are shown. (A) p-gal activity is detected only in the injected 
hemi-diaphra~ and is restricted to injection sites. Note also that the injected side shows staining from the costal margin to the central tendon. 
(B) Stained fibers are present hroughout he thickness of the muscle (see also Fig. 2a and c). Magnifications are x 9 (A) and x 209 (B). 
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Fig. 2. Sub-epimysial injection causes minimal muscle fiber damage. A/B and C/D represent serial cross-sections of diaphragm muscle injected with 
IacZ reporter gene and Sd later stained for B-gal activity (A,C), H & E (B), or embryonic and neonatal isofotms of MyHC immunoreactivity (D). 
Note that muscle fibers expressing the reporter gene are found throughout he thickness of the diaphragm (A,C) and that these fibers do not show 
signs of damage (B,D). Some muscle fibers display signs of damage as evidenced by centrally located myonuclei (see arrows in E and G). Damaged 
fibers were few and restricted to the most superficial part of the muscle adjacent o the site of injection. (F) shows a muscle cross-section area stained 
for the presence of embryonic and neonatal isoforms of MyHC; few immunoreactive fibers are present (arrows). Magnifications are x209 
(A,B,C,D,G) and x 105 (E,F). 
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expression vectors to prevent or reverse pathological 
changes in the mdx diaphragm. Based on the recent 
finding that expression of human dystrophin can cor- 
rect the myopathic phenotype in transgenic mdx mice 
[22,23], gene therapy using dystrophin expression con- 
structs appears to be a promising avenue for improving 
function in muscles of DMD patients. 
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